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Mosaic mutations present in the germline have important implications for reproductive risk and disease transmission. We
previously demonstrated a phenomenon occurring in the male germline, whereby specific mutations arising spontaneously
in stem cells (spermatogonia) lead to clonal expansion, resulting in elevatedmutation levels in sperm over time. This process,
termed “selfish spermatogonial selection,” explains the high spontaneous birth prevalence and strong paternal age-effect of
disorders such as achondroplasia and Apert, Noonan and Costello syndromes, with direct experimental evidence currently
available for specific positions of six genes (FGFR2, FGFR3, RET, PTPN11, HRAS, and KRAS). We present a discovery screen to
identify novel mutations and genes showing evidence of positive selection in the male germline, by performing massively
parallel simplex PCR using RainDance technology to interrogate mutational hotspots in 67 genes (51.5 kb in total) in 276
biopsies of testes from five men (median age, 83 yr). Following ultradeep sequencing (about 16,000×), development of a
low-frequency variant prioritization strategy, and targeted validation, we identified 61 distinct variants present at frequen-
cies as low as 0.06%, including 54 variants not previously directly associated with selfish selection. The majority (80%) of
variants identified have previously been implicated in developmental disorders and/or oncogenesis and include mutations
in six newly associated genes (BRAF, CBL, MAP2K1, MAP2K2, RAF1, and SOS1), all of which encode components of the RAS-
MAPK pathway and activate signaling. Our findings extend the link betweenmutations dysregulating the RAS-MAPK path-
way and selfish selection, and show that the aging male germline is a repository for such deleterious mutations.
[Supplemental material is available for this article.]
The timing, location, and functional effects of spontaneous muta-
tions determine the distribution and phenotypes of mutant cells
within the body. This can have a variety of impacts on the health
of an individual and, potentially, their offspring. Spontaneous
mutations occurring during early post-zygotic development lead
to widespread tissue mosaicism that, depending on context, may
be phenotypically undetectable or cause so-called “somatic” disor-
ders (Campbell et al. 2015). Such early post-zygotic mosaicism oc-
curs commonly, with up to 22% of apparently de novo point
mutations (DNMs) detectable in a child’s blood sample likely to
have occurred after fertilization (Acuna-Hidalgo et al. 2015;
Krupp et al. 2017). A corollary is that a further ∼4%–10% of
DNMs and∼4%of copy-number variants (CNVs) present in a child
can be detected at a low level in one of the parent’s somatic (usu-
ally blood or saliva) samples and are therefore in fact inherited; as
these would have occurred early during parental post-zygotic de-
velopment (before the separation of the somatic and gonadal lin-
eages), they are associated with a significant risk of recurrence
(Campbell et al. 2014; Acuna-Hidalgo et al. 2015; Rahbari et al.
2016; Krupp et al. 2017). In contrast, spontaneous mutations oc-
curring post-natally contribute to tissue-specific low-level mosai-
cism, the formation of benign tumors, or cancer, depending on
the functional consequence(s) of the acquired mutation(s), the
clonal dynamics of the tissue involved, and the state of the niche
(Klein et al. 2010a; Vermeulen et al. 2013; Holstege et al. 2014;
Swanton 2015). This latter phenomenon has been documented
in apparently healthy somatic tissues that display stem cell re-
placement (e.g., skin, colon, small intestine, and blood), where
low levels (∼1%–10%) of clonal mutations are prevalent and their
incidence and frequency increase with age (Hafner et al. 2010;
Laurie et al. 2012; Genovese et al. 2014; Jaiswal et al. 2014;
Martincorena et al. 2015, 2017; McKerrell et al. 2015; Acuna-
Hidalgo et al. 2017; Coombs et al. 2017; Zink et al. 2017).
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Analogous to the post-natal occurrence of somaticmutations,
we previously demonstrated a similar phenomenon, termed self-
ish spermatogonial selection, that occurs in the testes of adult
men as they age. However, because the testis contains germ cells
that, upon fertilization, will carry the genetic information across
generations, this process has important reproductive implications,
being associated with an increased prevalence of pathogenic
DNMs in the next generation. Despite the relatively low average
human germline pointmutation rate of∼1.2 ×10−8 per nucleotide
per generation (Kong et al. 2012; Goldmann et al. 2016; Jonsson
et al. 2017), specific “selfish” DNMs in FGFR2, FGFR3, HRAS,
PTPN11, and RET are observed up to 1000-fold more frequently
in offspring (Goriely and Wilkie 2012). These pathogenic muta-
tions, which cause developmental disorders that show an extreme
paternal bias in origin and an epidemiological paternal age-effect
(collectively referred to as PAE disorders; e.g., achondroplasia;
Apert, Costello, and Noonan syndromes; multiple endocrine neo-
plasia type 2a/b), are identical (or allelic) to oncogenic driver mu-
tations in tumors (Goriely and Wilkie 2012). We have proposed
that although they arise at the normal background rate in male
germline stem cells (spermatogonia), selfish mutations alter the
behavior of spermatogonia within the testis. In a process akin to
oncogenesis, these gain-of-function mutations provide a selective
advantage that may involve increasing the rate of symmetrical di-
visions of the mutant spermatogonia (Qin et al. 2007; Choi et al.
2008, 2012; Giannoulatou et al. 2013; Yoon et al. 2013; Martin
et al. 2014), leading to their clonal expansion over time, which re-
sults in increased apparent mutation levels in sperm with age
(Goriely and Wilkie 2012; Maher et al. 2014).
Three methods have previously been used to detect selfish
mutations in the male germline, each of which has been limited
in their ability to evaluate the process at scale: (1) quantification
in sperm, (2) quantification in testis biopsies, and (3) direct identi-
fication in seminiferous tubules. Detecting selfish mutations in
sperm, in which individual mutations are present at levels rang-
ing from 10−3 to <10−6, requires ultrasensitive techniques that
have limited reliable quantitative analysis to small regions of 1–6
nucleotides across five locations in FGFR2 (×2) (Goriely et al.
2003, 2005; Yoon et al. 2009), FGFR3 (×2) (Tiemann-Boege et al.
2002; Goriely et al. 2009), and HRAS (Supplemental Table S1;
Giannoulatou et al. 2013). To circumvent the technical challenges
caused by mutational dilution within an entire ejaculate, muta-
tions may alternatively be identified following systematic dissec-
tion and sequencing of DNA extracted from discrete testicular
biopsies. Germ cells (from diploid spermatogonia to haploid sper-
matozoa) are located in long (up to ∼80 cm) highly convoluted
and tightly packed seminiferous tubules, comprising approximate-
ly 300–500 per testis (Glass 2005). As clonally expanding mutant
spermatogonia are physically restricted to the tubules in which
they arise, their geographical distribution within the testis is con-
fined to specific regions: The existence of such localized foci has
been demonstrated for selfish mutations in four genes (FGFR2,
FGFR3, PTPN11, RET) (Qin et al. 2007; Choi et al. 2008, 2012;
Dakouane Giudicelli et al. 2008; Shinde et al. 2013; Yoon et al.
2013; Eboreime et al. 2016). Finally, mutant clones have been
directly visualized in sections of formalin-fixed paraffin-embedded
(FFPE) normal human testes using immunohistochemical ap-
proaches to reveal abnormal expression of spermatogonial anti-
gens (Lim et al. 2012; Maher et al. 2016a). Microdissection of
tubules exhibiting enhanced antigen staining and subsequent
whole-genome amplification facilitated the screening of over
100 genes, identifying nine new selfish mutations, including
one in a novel gene (KRAS) (Supplemental Table S1). However,
this approach is limited both by the need to source fixed testis sam-
ples with good tissue morphology and DNA preservation and by
the high threshold required for successful immunohistochemical
detection (Maher et al. 2016a,b).
Owing to the limitations outlined above, experimental evi-
dence of clonal expansion has so far been restricted to activating
mutations at 16 codons in only six genes (Supplemental Table
S1), all encoding members of the receptor tyrosine kinase (RTK)-
RAS-MAPK signaling pathway. Here, we hypothesized that other
variants dysregulating the RAS-MAPK pathway, and/or other path-
ways controlling spermatogonial stem cell homeostasis, may be
under positive selection in the male germline (Goriely and
Wilkie 2012; Goriely et al. 2013). To reduce the required assay sen-
sitivity compared with bulk semen analysis, and hence substan-
tially widen the extent of the genomic target that could feasibly
be analyzed in a single experiment, we exploited approach 2
above. By combining systematic dissection of testicular biopsies
with massively parallel simplex PCR and ultradeep sequencing of
mutational hotspots in 67 genes, we present themost comprehen-
sive survey of mutations clonally enriched in the human testis to
date.
Results
To perform a discovery screen to identify novel mutations and
genes under selection in the male germline, we systematically
biopsied human testes (with no known phenotypic indicators) fol-
lowing the experimental design summarized in Supplemental
Figure S1. A total of 276 small biopsies (∼60–180 mm3) from five
men (age range, 34–90 yr; median, 83 yr) were screened by ultra-
deep Illumina sequencing (about 16,000× post-filtering) of a
panel of candidate loci (corresponding to 59.4 kb of targeted
genomic sequence across 500 amplicons, covering mutational
hotspots in 61 candidate genes and genomic regions of 10 nega-
tive control genes [neutral-test]; seeMethods for criteria used to in-
clude loci in screen), amplified using massively parallel simplex
PCR (RainDance Thunderstorm). To detect low-level mosaicism
in individual biopsies (∼0.1%–3.0%), thebackgroundat eachgeno-
mic location was independently estimated for all 431 (of 500)
amplicons (in 67 of 71 genes) that passed quality control (QC)
(Supplemental Table S2). After normalization, a statistical model
was applied to call outlier nonconsensus variants at each genomic
position (within each amplicon): A minimum threshold of 10
variant readsandmediancoverageofgreater than5000×was imple-
mented to reduce false-positive calls. As a conservative prioritiza-
tion strategy, only variants with two or more independent calls
were further studied, resulting in a set of 374 variant calls located
at 361 genomic locations (seeMethods). Visualization andmanual
curationofeachof thesecalls identified115higher-confidencecan-
didate variants, distributed at 105 genomic positions across 165
biopsies (all 115 variants are detailed in Supplemental Table S3).
As calling variants at low levels (<1%) is subject to PCR arti-
facts and sequencing errors (Minoche et al. 2011; Hestand et al.
2016; Salk et al. 2018), we developed a tiered strategy for further
variant prioritization. We reasoned that variants called indepen-
dently in overlapping amplicons or in sample replicates (12 biop-
sies were amplified and sequenced in duplicate) were least likely to
be artifactual (Tier 1 variants, Table 1). Eighteen of the 40 Tier 1
variants (with VAF ranging from 0.10% to 2.63%) were rescreened
by PCR or by using single-molecule molecular inversion probes
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Seventeen of the 18 (94%) variants were validated, suggesting the
great majority of Tier 1 variants are true-positive calls (Table 1;
Supplemental Table S3). Among the Tier 1 variants are five muta-
tions previously associated experimentally with selfish selection:
FGFR2 c.755C>G (p.Ser252Trp – Apert syndrome), c.758C>G
(p.Pro253Arg – Apert syndrome) and c.870G>T (p.Trp290Cys –
Pfeiffer syndrome), KRAS c.182A>G
(p.Gln61Arg – oncogenic), and PTPN11
c.215C>T (p.Ala72Val – oncogenic)
(Table 1). This strong enrichment for ca-
nonical examples of selfish mutations
(Supplemental Table S1) provided initial
validation of our experimental approach
and starting hypothesis.
Within the panel, the majority
(88.7%) of callable (i.e., excluding primer
sequences and amplicons with low QC)
regions were represented by a single
amplicon, and only 12 biopsies were se-
quenced in duplicate (Supplemental
Table S4): Hence, we next investigated
variants that were called in single ampli-
cons in two or more biopsies, at VAF of
≥0.2% in at least one biopsy (Tier 2).
Twenty-six Tier 2 variantswere identified
andwere rescreened by direct PCR ampli-
fication or smMIPs and ultradeep MiSeq
sequencing, 18 (69%) of which were
true positives (Table 1; Supplemental
Table S3). Notably, all (14/14) of the
known pathogenic variants were validat-
ed, but only four of the 12 variants with-
out prior disease association were true
positives. In biopsy 4D25, PTPN11
c.1504T>A (p.Ser502Thr – Noonan syn-
drome) was called as a single-nucleotide
variant, but on validation, it was identi-
fied as a double-nucleotide substitution
c.1504_1505delTCinsAA (p.Ser502Lys).
Next, 29 variants with a VAF of 0.1%–
0.2% called in a single amplicon in two
or more biopsies (Tier 3) were identified.
Only four of the 22 (18%) resequenced
Tier 3 variants were validated, suggesting
that in this lower frequency range, the
majority of calls are artifactual (Table 1;
Supplemental Table S3). Owing to the
low validation rate of variants with VAFs
of 0.1%–0.2%, none of the remaining
20 calls that exhibited VAF<0.1% (Tier
4) variants were rescreened for validation
(Supplemental Table S3).
Overall, we identified 61 distinct
variants that were classified as indepen-
dently validated in a total of 162 ana-
lyzed samples (corresponding to 111
mutation-positive testis biopsies) present
in 15 of the 67 genes that passed QC and
were analyzed in the experiment. Based
on the identification of the same variant
in testes sourced from different men, we
conclude that at least 72 independent
mutational events (clones) could be distinguished across the five
testes (Table 1; Fig. 1A–D; Supplemental Figs. S2, S3). Two variants
(FGFR2 c.755C>G (p.Ser252Trp) [no. 7] and KRAS c.35G>C
(p.Gly12Ala) [no. 18]) occurred in three testes and seven in two
testes (Fig. 1; Supplemental Fig. S2). All these variants either are




Figure 1. Distribution of validated variants in testis slices 1D (A), 2F (B), 4B (C), and 5J (D). Testicular
biopsy numbers are located to the left of each testis slice. Some biopsies were further dissected into two
pieces of which the orientation is unknown; these are indicated with a diagonal dashed line (e.g., Tes2F
30a,b). Each variant has a distinct number (as listed in Table 1) and is colored according to gene—FGFR2
(purple), FGFR3 (orange), KRAS (black), PTPN11 (blue), RET (pink), and newly associated gene (red)—and
is also indicated on the figure key. The size of each circle is proportional to the observed variant allele fre-
quency (VAF) in each biopsy as indicated by black dots on the figure key. Identical variants in different
biopsies have been connected by lines that likely track the seminiferous tubule trajectory across the testis
and therefore may represent a single “clonal event”; note that the path of the clone has been arbitrarily
drawn and may not represent the true trajectory of the tubule. Dark gray segments represent biopsies
thatwere not sequenced due to insufficientmaterial quality/quantity (seeMethods). Light gray segments
represent nontubular regions of tissue. The age of the individual from whom the testis was collected is
indicated on the figure (for further details on the testicular samples, see Supplemental Table S5). The re-
maining five slices of Tes4 are presented in Supplemental Figure S2. Tes3D is omitted as no variants were
identified. Variants are numbered in order of tier: Tier 1 (1–39), Tier 2 (40–57), Tier 3 (58–61). Letters in
brackets refer to variants associatedwith germline disorders [G] and/or reported in the COSMIC database
[C]; for further details, see also Table 1 and Supplemental Table S3.
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are known hotspots in cancer (COSMIC) that may be associated
with lethal or as-yet undescribed congenital disorders (Table 1).
Figure 2 details all validated variants for the two genesmost highly
represented in this list: FGFR2 and PTPN11 (15 independentmuta-
tional events responsible for 10 distinct variants in FGFR2 [encod-
ing nine pathogenic protein changes] and 22 independent
mutational events of 20 distinct variants in PTPN11). Their relative
locations on the respective protein products show considerable
overlap with mutational hotspots previously associated with
developmental disorders and cancer. The corollary is that our ob-
servations of these mutations in testes are likely to be relevant to
the biological origins of the cognate diseases. Similar plots for 13
other genes with validated variants are presented in Supplemental
Figure S3.
Previous studies have reported that selfish mutations show a
localized focal distribution in the testis (Qin et al. 2007; Choi et al.
2008, 2012; Dakouane Giudicelli et al. 2008; Lim et al. 2012;
Shinde et al. 2013; Yoon et al. 2013; Eboreime et al. 2016), with
mutations in adjacent biopsies likely tracking single seminiferous
tubules and representing the same clonal event (Maher et al.
2016a). By use of the geographical register of themultiple biopsies,
the spatial distribution of each variant across the testicular biopsies
was investigated (Fig. 1; Supplemental Fig. S2). For example, in six
of 153 biopsies across three slices from Tes4, we identified a KRAS
c.35G>A (p.Gly12Asp) mutation (no. 19). KRAS c.35G>A is one
of the most frequently reported substitutions in cancer (more
than 14,000 records in COSMIC v82), and post-zygotic KRAS
c.35G>A mutations have been reported to cause arteriovenous
malformations of the brain (Nikolaev et al. 2018) and linear nevus
sebaceous syndrome (Wang et al. 2015), but it has never been re-
ported as a constitutional mutation. In slice 4B (slice B of testis
4) (Fig. 1C; Supplemental Figs. S2, S3F), thisKRASmutationwas de-
tected at VAFs ranging from 0.26% to 1.82% in four adjacent biop-
sies, suggestive of an expansion of a mutational event tracking
along the length of a single seminiferous tubule. The same KRAS
variant was also detected in two neighboring biopsies from slices
4D and 4E, apparently at a distance from the larger clone in slice
4B (Supplemental Fig. S2); this smaller clone may represent a dis-
tinct mutational event having occurred in an independent tubule,
but the resolving power of the experiment does not exclude the
possibility that this is a large clonal event spreading along the
length of a single seminiferous tubule.
Owing to the convolutedpackingof the seminiferous tubules,
individual testicular biopsies contain segments ofmultiple individ-
ual tubules, and in 43 biopsies, more than one variant was identi-
fied (Fig. 1A–D; Supplemental Fig. S2; Supplemental Table S3).
Mutations with similar distributions across multiple biopsies may
represent clones either within the same tubule or in distinct inter-
mingled tubules running alongside each other. For example, two
distinct mutations,MAP2K2 c.373T>A (p.Cys125Ser) (oncogenic)
and PTPN11 c.215C>A (p.Ala72Asp) (oncogenic), are both found
in the adjacent biopsies 2F11 and2F16 (Fig. 1B),with the lattermu-
tation extending into theneighboring biopsy 2F21. In Tes4, four of
the six biopsies positive for the oncogenic KRAS c.182A>G
(p.Gln61Arg) mutation (4E18, 4E25, 4F27, 4G1) were also positive
for a synonymous variant in LRP5 (c.291C>T (p.Ala97=); no prior
disease association) (Supplemental Figs. S2, S4).
In contrast to selfish mutations that occur in adult spermato-
gonia and are therefore restricted to the seminiferous tubules in
which they arise, “classical” post-zygotic mosaic mutations occur-
ring in embryonic primordial germ cells, before the formation of
the seminiferous tubules, are expected to have a wider geographi-
cal distribution in one or both testes. We found one suggestive ex-
ample of this, an NF1 c.2280G>A (p.Met760Ile) variant, which
exhibited a pattern of occurrence in Tes4 distinct fromall the other
identified mutations. The variant was originally called in nine bi-
opsies at relatively high VAF (median, 1.1%; range, 0.9%–2.1%)
(Supplemental Fig. S2), and inspection of the mutation frequency
in each sample (Supplemental Fig. S5) showed numerous other bi-
opsies in Tes4 with elevated VAFs, compatible with an earlier post-
zygotic mosaic event. Unfortunately, no other tissue was available
from this individual to test whether the variant was restricted to a
single testis and/or to the germline tissue.
To explore the relationship between mutational events iden-
tified using RainDance technology (which inherently involves de-
struction of the tissue structure of the testis) and the occurrence of
mutations in individual seminiferous tubules, we exploited the
availability of adjacent FFPE material for two of the testes. In
Tes1D, our deep-screening strategy identified a FGFR2 c.1024T>
A (p.Cys342Ser) variant at VAFs ranging from 0.26% to 2.95% in
seven contiguous biopsies, suggestive of a clonal event tracking a
single seminiferous tubule across the testis (Figs. 1D and 2, variant
44). For this testis, we had previously studied the adjacent FFPE tis-
sue block (Tes1-1 described by Lim et al. 2012; Maher et al. 2016a)
using immunohistochemical staining for markers of selfish clones
(enhanced MAGEA4 and pAKT immunostaining), followed by
laser capturemicrodissection and targeted resequencing.Weprevi-
ously identified and validated the identical FGFR2 variant, suggest-
ing that this large mutant clone is present within a significant
portion of a single seminiferous tubule that tracks across adjacent
testis slices (Maher et al. 2016a). To seek further examples, we un-
dertook a new analysis of putative mutant clones within Tes2E, a
FFPE tissue block adjacent to the Tes2F slice, to identify individual
tubular cross-sections exhibiting enhanced MAGEA4 immunos-
taining (Fig. 3A); laser capture microdissection of six distinct
groups of tubular cross-sections followed by PCR and Illumina
sequencing confirmed the presence of the FGFR2 c.755C>G
(p.Ser252Trp – Apert syndrome) (Fig. 3C,E) and PTPN11 c.214G>
C (p.Ala72Pro – Noonan syndrome) mutations in distinct en-
hanced MAGEA4-tubules (Fig. 3D,F), consistent with the geo-
graphic location of these specific variants identified by deep
sequencing in the adjacent Tes2F slice (Fig. 3B). For the three other
testes, FFPE blocks were not available.
Discussion
Wepresent a new broad-scale approach to studying clonal de novo
germline mutations directly in human adult testes, the tissue
where the majority of DNMs originate. By usingmassively parallel
multiplex PCR and ultradeep sequencing followed by the imple-
mentation of a statistical prioritization calling strategy, we identi-
fied 61 different variants in a total of 111 mutation-positive
testicular biopsies, 59 of which encode nonsynonymous substitu-
tions (Table 1).
Several observations support the notion that the mutations
identified are enriched for clonal events that are promoted by pos-
itive selection of mutant stem cells via the phenomenon of selfish
spermatogonial selection. Out of the 61 validated variants (Table
1), 43 are located in five (FGFR2, FGFR3, KRAS, PTPN11, RET) of
the six genes associated with strong prior experimental evidence
for this process (Supplemental Table S1). As detailed in Table 1
and illustrated in Figure 2 and Supplemental Figure S3, the vastma-
jority of variants identified across these five genes overlap with




 Cold Spring Harbor Laboratory Press on February 20, 2019 - Published by genome.cshlp.orgDownloaded from 
AB
Figure 2. Spontaneous mutations in FGFR2 (A) and PTPN11 (also known as SHP2; B) identified in testicular biopsies. (A, I ) Ten validated variants posi-
tioned along the amino acid sequence of FGFR2 (x-axis, see panel V), ranging in VAF from 0.06% to 2.95% (y-axis), identified in Tes1D, Tes2F, and
Tes4. Numbers correspond to those in Table 1; two different variants (c.870G>C or T) predicted to cause the same p.Trp290Cys substitution (nos. 11,
12) were identified. (II) Relative location and length of amplicons used to sequence main hotspots of FGFR2 are plotted on the x-axis. Median coverage
per amplicon is plotted on the y-axis. All amplicons had median coverage above the cut-off (red dashed line) of 5000×. (III) Number of reported consti-
tutional variants encoding amino acid substitutions in FGFR2 associatedwith developmental disorders (sqrt scale) (updated fromWilkie 2005). (IV) Number
of reported somatic amino acid substitutions in FGFR2 in cancer (COSMIC v82). (V) Protein domains of FGFR2. Annotations and protein structure are based
on transcript ID NM_000141 and Uniprot ID P21802 (v2017_01), respectively. (B, I) Twenty validated variants positioned along the amino acid sequence
of SHP2 (x-axis, see panel V), ranging in VAF from 0.09% to 1.02% (y-axis), identified in Tes1D, Tes2F, and Tes4. (II) Location and size of amplicons used to
sequencemain hotspots of PTPN11 are plotted on the x-axis. Median coverage per amplicon is plotted on the y-axis. All amplicons except one hadmedian
coverage above the cut-off of 5000×. (III) Number of reported constitutional variants encoding amino acid substitutions in SHP2 associated with devel-
opmental disorders (sqrt scale). (IV) Number of reported somatic amino acid substitutions in SHP2 in cancer (COSMIC v82). (V) Protein domains of
SHP2. Annotations and protein structure are based on transcript ID NM_002834 and Uniprot ID Q06124 (v2017_01), respectively.
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suggestive of a functional role via a gain-of-function mechanism.
The most commonly observed individual mutation was FGFR2
c.755C>G (p.Ser252Trp–Apert syndrome)detected in23biopsies.
In this and other cases, the identification of identical variants in
multiple neighboring testis biopsies (Fig. 1; Supplemental Fig. S2)
is supportive of clonal expansion along the length of the seminif-
erous tubules, and in three cases, this process could be directly val-
idated at a cellular level by visualizing the selfish expansion
characterized by enhancedMAGEA4 staining in the adjacent testis
block (Fig. 3; Maher et al. 2016a). The largest number of mutations
was observed for PTPN11 (encoding the SHP2 tyrosine phospha-
tase), in which we identified 20 different variants (across 33 biop-
sies) (Table 1; Fig. 2B). We observed 12 distinct variants located
within the N-SH2 domain of SHP2, a region of the protein known
to repress the catalytic phosphatase domain in its wild-type state
(Neel et al. 2003), including each of the possible nucleotide
substitutions at PTPN11 c.215C encoding three distinct amino ac-
ids (p.Ala72Asp, p.Ala72Gly, and p.Ala72Val) that have been asso-
ciatedwithNoonansyndromeoroncogenesis. The largenumberof
different de novo variants is consistent with epidemiological
data that concur that PTPN11-associated
Noonan syndrome mutations have a
high spontaneous birth prevalence
(about one in 10,000 births) (Goriely
and Wilkie 2012). We also identified
two dinucleotide (tandem base) sub-
stitutions in PTPN11: Both the
c.226_227delGAinsCT (p.Glu76Leu) (no.
30) and the c.1504_1505delTCinsAA
(p.Ser502Lys) (no. 55) variants encode
amino acid substitutions that, owing to
the nature of the genetic code, cannot
arise from single-nucleotide changes.
These observations are reminiscent of
other previously described selfish muta-
tions encodedbydoubleand triple substi-
tutions, which in some cases were shown
to result via a “double-hit” mechanism
(Goriely et al. 2005; Goriely and Wilkie
2012; Giannoulatou et al. 2013). In hu-
mans, the de novo tandem mutation
rate is estimated to be ∼0.3% of the sin-
gle-nucleotide variant rate (Besenbacher
et al. 2016); in this small setof61variants,
we find an approximately 10-fold enrich-
ment over the background rate.
Given this strong support for posi-
tive clonal selection of pathogenic vari-
ants in previously known selfish genes,
the next question is whether the other
18 validated variants present in novel
candidate genes might also signal the
presence of selfish selection. We first ex-
cluded from consideration one variant,
NF1 c.2280G>A p.(Met760Ile) (no. 49),
which presented with a different pattern
of occurrence characterized by an ex-
tended geographical distribution across
about one-third of the testis from indi-
vidual Tes4, raising the possibility of an
early post-zygotic (as opposed to adult-
onset) mutational event (Supplemental
Fig. S5). Although this NF1 variant exhibits a high CADD score
(24.6), has been reported in one case of lung cancer (Redig et al.
2016), and is located within the cysteine-serine–rich domain, a re-
gion where several missense mutations associated with breast can-
cer and neurofibromatosis have been identified (Koczkowska et al.
2018), its pathogenic status—and potential for positive selection—
remains uncertain.
Of the remaining 17 variants, all but three are accounted for
by six genes (BRAF, CBL, MAP2K1, MAP2K2, RAF1, and SOS1) en-
coding members of the RAS-MAPK pathway, among which nine
variants have previously been reported in either congenital dis-
orders or cancer (Table 1; Supplemental Fig. S3). Moreover, for
several variants (BRAF p.Gly469Ala, MAP2K1 p.Lys57Asn and
p.Gln56Pro, MAP2K2 p.Cys125Ser, RAF1 p.Ser257Leu and
p.Pro261Ala), direct biochemical evidence of a dominant gain-
of-function activity is available (Wan et al. 2004; Kobayashi et al.
2010; Van Allen et al. 2014; Arcila et al. 2015). In fact, only three
validated variants (nos. 1, 2, 47), for which evidence of in-
volvement in selfish selection is weak or can be ruled out, were
found in genes (APC, AKT3, LRP5) that function outside the
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Figure 3. Visualization of mutant tubules in Testis 2. (A) A 5-µm-thick section from Tes2E, a FFPE block
of tissue adjacent to the testis slice 2F (B), immunostained with anti-MAGEA4 antibody to label sperma-
togonia. Seminiferous tubules with enhanced MAGEA4 immunopositivity, suggestive of the presence of
mutant clones are labeled with small red pins and boxed. Scale bar, 5 mm. (C,D) High-magnification
view of cross-sections with MAGEA4-enhanced immunopositivity in two localized areas are labeled
with dotted lassoes representing the laser-microdissected regions. Scale bars, 100 µm. (E,F) Results
from targeted resequencing of the microdissected seminiferous tubules labeled by dotted lassoes in C
and D, respectively, viewed in integrated genome viewer (IGV), with local genomic sequence context
indicated at the bottom. VAF of mutant reads is indicated on the top using color specific for each base
pair; spontaneous pathogenic FGFR2 c.755C>G (no. 7; E) and PTPN11 c.214G>C (no. 25; F) variants
were identified in DNA extracted from microdissected tubule cross-sections, but not in DNA from the
whole-tissue section. Comparison of the MAGEA4 section (A) with adjacent testis slice 2F from the
RainDance screen (B; the same image as in Figure 1B but showing only the targeted FGFR2 and
PTPN11 mutations) shows that both variants match to a mutation previously identified in the corre-
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RTK-RAS-MAPK pathway (see Supplemental Note). Hence, al-
thoughonly41.9%of the callable sequenceof ourpanel comprised
RTK-RAS-MAPK candidate genes, 95% (57/60) of the validated var-
iants represented known or very likely pathogenic changes within
members of this signaling pathway (P value =4.233×10−13, two-
tailed Fisher’s exact test; logistic regression coefficient = 1.69, P val-
ue =6.363×10−15) (see Supplemental Tables S7, S8; Supplemental
Methods), reinforcing the proposal that activation of the RAS-
MAPK pathway is the predominant mechanism underlying selfish
spermatogonial selection (Goriely et al. 2003, 2009; Goriely and
Wilkie 2012; Maher et al. 2016a). Mutations in other core cellular
pathways screened here either may not be associated with positive
selection in human testes or may lead to milder clonal expansions
that will require more sensitive screening approaches to uncover.
In addition, there may be positively selected mutations in other
genes that were not targeted in this screen due to the limited panel
size. Although it can be difficult to formally distinguish signals of
selection from normal turnover/neutral drift dynamics whereby
the random loss of some clones is compensated by the expansion
of others over time (Klein et al. 2010b; Simons 2016; Zink et al.
2017), the highly significant enrichment of functionally signifi-
cant (biochemically activating)mutations affecting a single signal-
ing pathway argues against a neutral process.
Among the variants we identified, we observed a high propor-
tion of strongly oncogenic mutations, with 23 of the 35 nonsy-
nonymous variants reported in COSMIC (v82) having never
been described as constitutional mutations (Table 1). Strong
gain-of-function mutations would be more likely to promote effi-
cient expansion of spermatogonial stem cells and result in larger
clones that are easier to detect (Goriely et al. 2009; Giannoulatou
et al. 2013). However, in order to be transmitted, the mutations
must be compatible with formation of functional sperm and
with embryonic development.We previously showed that tubules
with spermatogonia harboring strongly oncogenic variants are as-
sociated with reduced numbers of post-meiotic cells (Maher et al.
2016a). This would represent amechanism bywhich the testis “fil-
ters” the transmission of pathogenicmutations across generations,
although proof of this concept would require the development of
ultrasensitive assays to screen large numbers of sperm samples. It is
noteworthy that despite the relative abundance of strongly onco-
genicmutations in the adultmale germline, testicular tumors orig-
inating from adult spermatogonia (spermatocytic tumors) are
extremely rare, with an incidence of about one per million men
and are mostly benign in nature (Ghazarian et al. 2015; Giannou-
latou et al. 2017).
In this study, the majority of biopsies analyzed were from
older donors. Given that bothmutation occurrence and clonal siz-
es are anticipated to be age-related processes, we reasoned that
older individuals’ testes would be more suitable for a discovery
screen; i.e., they aremore likely to show a higher frequency of ran-
dommutational events, among which selfish variants would have
had time to expand to a clonal size amenable to direct detection.
Hence, the age range of the testes analyzed in this studywas highly
skewed, with >90%of biopsies being sampled from four older indi-
viduals (aged 71–90 yr) and the remaining, Tes5J, being sourced
from a 34-yr-old man. While for three of the older individuals
we identified multiple mutation-positive biopsies (Fig. 1; Supple-
mental Fig. S2), Tes5J from the younger man contained only two
mutation-positive biopsies—likely representing a single clonal
event—carrying the oncogenic CBL c.1211G>A (p.Cys404Tyr)
variant (at VAF 0.5%–0.6%), in keeping with the expectation
that the prevalence and size of mutant clones increases with
time (Fig. 1D). It was, however, surprising that no variants were de-
tected in Tes3D, given the advanced age of the donor (87 yr).
Although it is possible that this individualmayhave had a lowpro-
pensity to accumulation of selfish mutations, a more likely expla-
nation is that only a few atrophic seminiferous tubules with
hypospermatogenesis were present in this testis, a phenomenon
known as progressive tubular involution commonly described in
elderly men (Paniagua et al. 1987). Unfortunately, as no tissue
had been preserved for histological analysis (Supplemental Table
S5), we were unable to determine the status of spermatogenesis
in this testis.
Our study has several technical limitations. The majority of
variants identified were present at VAFs <1%, close to the typical
detection limits attributable to the error rates associated with
DNA damage (10−2–10−4) (Arbeithuber et al. 2016; Chen et al.
2017), PCR (10−4–10−6) (Hestand et al. 2016; Potapov and Ong
2017), and Illumina sequencing (∼10−3) (Minoche et al. 2011;
Salk et al. 2018). To account for such technical confounders, we
employed a conservative custom statistical approach to determine
the background error rate at each position and to prioritize variants
(Supplemental Fig. S1). Althoughwe confirmed variants with a fre-
quency as low as 0.06% using this approach, the majority (81.8%)
of the prioritized variants called in single amplicon at VAFs of
0.1%–0.2% (Tier 3) were false positives. In the 12 samples ampli-
fied and sequenced in duplicate, only seven of 15 variants were
called in both replicates (Supplemental Table S4). The best predic-
tor of true positives was the presence of a call in more than one
amplicon (100% validation rate); for calls in single amplicons,
the best predictor was the pathogenicity of the variant (17 of 18
[94.4%] pathogenic variants vs. five of 30 [16.7%] without prior
disease association validated). Broad-scale approaches that target
both DNA strands and use unique molecular indexes such as du-
plex sequencing (Kennedy et al. 2014) or smMIPs (used here to val-
idate a subset of variants) (Hiatt et al. 2013) represent valuable
alternatives to direct PCR amplification in future studies to reduce
background errors (Salk et al. 2018). Overall, 14% of the designed
amplicons did not pass QC (due to insufficient coverage and/or
mapping error), which included those targeting candidate PAE
mutations such as eight mutational hotspots in FGFR3, six in
PTPN11, one in RET, and other key hotspots in SKI (Shprintzen-
Goldberg syndrome), SETBP1 (Schinzel-Giedion syndrome), and
AKT1 (Proteus syndrome, oncogenesis). Although considered to
be the most frequently mutated nucleotide in the germline with
a birth prevalence of about 1:30,000 (Bellus et al. 1995), we did
not detect the FGFR3 c.1138G>A or c.1138G>C achondropla-
sia-associated mutations due to exclusion of this region because
of insufficient coverage (less than 5000×) (Supplemental Table
S2; Supplemental Fig. S3E).
In summary, this work represents a new approach to studying
DNMs directly in their tissue of origin. By utilizing the clonal na-
ture of mutations that leads to focal enrichment, we circumvented
the technical difficulties associated with calling DNMs in single
sperm or the poor DNA quality associated with immunopositive
tubules from FFPEmaterial. In a single biopsy, a whole population
of de novo mutations can be assessed. Studying mutations within
the testis facilitates identification of mutations and pathways un-
der positive selection in spermatogonia but that may be incompat-
iblewith life, either by impairing gamete differentiation and sperm
production or by causing early embryonic lethality. Our approach
reveals the prevalence and geographical extent of clonalmutations
in human testes, suggesting that the aging male germline is a re-
pository for functionally significant, often deleterious mutations.
Selfish de novo mutations in human testes
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Based on an estimated total birth prevalence of DNMs causing
developmental disorders of one in 295 (Deciphering Developmen-
tal Disorders Study 2017), such PAE mutations may contribute
5%–10%of the total burden of pathologicalmutations, depending
on paternal age. Investigating the clonal nature of spontaneous
testicular variants also provides insights into the regulation of
the poorly studied human spermatogonial stem cell dynamics
and into how spontaneous pathogenic mutations hijack homeo-
static regulation in this tissue to increase their likelihood of trans-
mission to the next generation.
Methods
A schematic of the experimental protocol is presented in
Supplemental Figure S1, and detailed methodology is provided
in Supplemental Methods.
Sample preparation and sequencing
Testes with no known phenotypic indicators and sourced with ap-
propriate ethics approval from fivemen aged 34, 71, 83, 87, and 90
yrwere cut into slices∼3–5mmthick,whichwere further dissected
into 21–36 biopsies (Supplemental Table S5). DNA of sufficient
quantity and quality was prepared from a total of 276 biopsies
(Tes1D [34 biopsies], Tes2F [30 biopsies], Tes3D [32 biopsies],
Tes4B-4G [153 biopsies from six slices], Tes5J [27 biopsies]). A
66.7-kb panel of 500 genomic regions in 71 genes was designed.
The panel comprised mutational hotspots in the six established
PAE genes; genes encoding other RTKs and members of the RAS-
MAPK signaling pathway; genes in other pathways associated
with spontaneous disorders that display narrow mutational spec-
tra suggestive of gain-of-function effects but lacking epidemiolog-
ical data for paternal age-effect; oncogenes commonly mutated in
cancer, some of which are also associated with germline disorders;
and regions of 10 “neutral-test” genes. Of note, a total of nine var-
iants in the “neutral-test” set were long-listed following filtering
(Supplemental Table S3), seven of which were in Tier 4. The two
Tier 2 variants in the “neutral-test” set were rescreened and shown
to be false-positive calls (Supplemental Note). Details of all target-
ed regions and primers used for amplification are provided in
Supplemental Table S6.
The 500 target regions were amplified by massively parallel
simplex PCR using the RainDance Thunderstorm target enrich-
ment system. Droplets containing up to five primer pairs were
mergedwith gDNA droplets to generate an average of 2 ×106 drop-
lets per sample (525,000 haploid genomes; average of one haploid
genomeper three to four droplets; about 1000 genomes/individual
primer pair). Following the merge, libraries were PCR-amplified
and purified, and tailed libraries for Illumina sequencingwere con-
structed by PCR using a set of 8-bp barcoded adaptors (BC1-18). A
total of 288 samples from 276 biopsies (12 biopsies were amplified
in duplicate) (Supplemental Table S5) were amplified across six
ThunderStorm enrichment chips (48 samples each) and subse-
quently ultradeep sequenced (about 22,000×) on two flow cells
(16 lanes; 18 samples per lane) of IlluminaHiSeq 2000 (2×100 bp).
Sequence alignment, and variant calling and prioritization
Reads passingQC (on average 86%of reads)were aligned to the hu-
man genome (hg19) using BWA-MEM version 0.7.10 (Li 2013)
with default parameter settings. As only genomic regions of well-
characterized disease geneswere interrogated in this study, realign-
ment of the data to the GRCh38 assembly would not significantly
affect the identification of low-level de novo variants. Pileup was
then performed for each amplicon independently. After trimming
of primer sequences, reads with more than 10 nonreference bases
were removed (<1% of coverage on average). To avoid double-
counting reads at positions where read 1 and read 2 overlapped,
only the base with the higher quality was considered. To reduce
false-positive calls, only variants supported by at least 10 reads
were called. To account for the technical confounders, the data
were normalized (accounting for flow cell, lane, and average base
quality at each position) using a simple linear model, and the me-
dian effect was removed from each lane to reduce the background
signal.
Each nonreference nucleotide at each genomic position
across the 288 samples was tested independently in each amplicon
that passed QC (supplemental custom pipeline; https://github.
com/zd1/raindance). Variant prioritization was performed using
a P-value cutoff of –log10P>20, which resulted in a total of
19,625 genomic positions with at least one nonreference call.
Further filtering was performed to remove potential sources of ar-
tifacts: samples or amplicons with an excessive number of variants
(Supplemental Fig. S6), calls positioned 1 base from the amplifica-
tion primer’s 3′-end, calls with a maximumVAF of ≥3%, and posi-
tions with a median depth coverage across all samples below
5000× (Supplemental Table S2). This resulted in a total of 5729
calls (5659 distinct variants) at 5421 positions (in a total of 431
amplicons, corresponding to 51.5 kb of unique genomic sequence,
across 67 genes), themajority (90.2%) of whichweremade in a sin-
gle amplicon and sample. As singleton calls were more likely to
represent PCR or sequencing artifacts, we further prioritized calls
made in two ormore samples and/or present in overlapping ampli-
cons. Variant calls showing evidence of library-specific batch or se-
quence misalignment effects were excluded from further analysis.
The remaining 115 variants at 105 genomic positions were anno-
tated with ANNOVAR version 2015Jun17 (Wang et al. 2010) (for
full details of the 115 variants, see Supplemental Table S3). If a var-
iant was covered by more than one amplicon or was present in a
replicated biopsy, the VAFs presented in Table 1 and all figures rep-
resent the mean allele frequency of the called variants.
Variant validation
DNA from at least one putative-positive biopsy sample and at least
eight control samples (unrelated blood gDNA and gDNA fromoth-
er testicular biopsies) was screened by PCR amplification using dif-
ferent primers from those used in the RainDance experiment or by
smMIPs capture and ultradeep sequencing (about 30,000×) using
Illumina MiSeq 300v2 (PCR) or 150v3 (smMIP) kits (primer and
smMIP details in Supplemental Table S6). Immunohistochemical
staining of FFPE testis slices to identify tubules with enhanced
spermatogonial MAGEA4 staining, followed by laser capture mi-
crodissection and DNA extraction, was performed as described
(Maher et al. 2016a). DNA was subsequently amplified by PCR us-
ing CS-tagged primers and barcoded for Illumina MiSeq 300v2
sequencing.
Data access
Raw sequencing FASTQ files from this study have been submitted
to the European Nucleotide Archive (ENA; https://www.ebi.ac.uk/
ena) under accession no. PRJEB28332.
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